Pfizer, Moderna and BioNTech
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
The Pfizer/BioNTech Comirnaty price-hike is not entirely unexpected. Although the projected cost is far more than what CVS – which recently acquired Signify Health – charges for a flu shot ...
Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...
Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...
while antiviral treatment Paxlovid was $727 million for the quarter. Pfizer makes the Comirnaty vaccine with German partner BioNTech.
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read why PFE stock is a Sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback